There’s “just too many early stage companies going public”, or so goes one of the most common lamentations about the current state of the biotech market. …
BioTech Times™ is part of GroupWeb Media Network. © 2025 GroupWeb Media LLC
Latest in Products
-
-
By Deanna Petersen, CBO of AVROBIO, and Ted Tanaka, consultant with Tanaka International LLC, as part of the From The Trenches feature of LifeSciVC Imagine yourself …
-
By Robert Clarke, CEO of Kinaset, as part of the From The Trenches feature of LifeSciVC. Although I intend to shy away from the cult of …
-
By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC By all accounts, 2022 did not start according to …
-
By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotechnology, especially of late, requires us to prevail over …
-
By Deanna Petersen, CBO of AVROBio, as part of the From the Trenches feature of LifeSciVC Gene therapy’s tremendous potential to transform the treatment of both …
-
By Aoife Brennan, CEO of Synlogic Therapeutics, as part of the From The Trenches feature of LifeSciVC Earlier this month, I attended the J.P. Morgan 41st …
-
By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotwitter is great for healthy debates. The most recent …
-
By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC I remember vividly my first vacation with the man who …
-
By Bob Clarke, CEO of Kinaset Therapeutics, as part of the From The Trenches feature of LifeSciVC As we enter the final leg of 2023, navigating …